Valeant Pharmaceuticals Intl Inc. Sure Has Fight in it

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) continues to manage its debt, but will its product-development pipeline be enough to help it achieve its former greatness?

| More on:
The Motley Fool

It’s hard not to admire a company that is fighting hard to prove that it’s not a failure and attempt to achieve the type of greatness it once had. That’s the story of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX), a company that at one time was known as the Hedge Fund Hotel before coming under attack for price-gouging tactics.

Now, with its new CEO Joseph Papa and a mission to clean up the balance sheet and return this company to success, we can clearly see that Valeant has plenty of fight in it. And even when the markets suggest the company may be down, it keeps moving forward.

The big argument against Valeant has always been debt. Before the price-gouging accusations, Valeant had funded its aggressive growth by borrowing tens of billions of dollars. That strategy made sense. If Valeant borrowed money to buy a company that was selling its drug for $100 per dose and then increased the price of that drug to $500 per dose, it would come out ahead.

Valeant has been getting rid of that debt. Papa promised to get rid of US$5 billion in debt by February 2018. Valeant has already paid off US$6 billion. That’s a big feat, because Valeant was sitting on US$32 billion when Papa took over.

Back in December, Papa took steps to buy the company more time to pay off its debt. In 2020, US$4.4 billion of debt is due; in 2021, Valeant owes US$3.2 billion; in 2022, it owes US$6.6 billion; in 2023, it owes US$6 billion; Valeant owes an additional US$6.3 billion from 2024 on. Papa reduced that 2020 amount to under US$3 billion, and though the interest rate has been increased on those notes, Valeant has more freedom to move assets around as it sees fit.

I honestly wasn’t sure what to expect from Valeant when it came to paying off debt, but management has certainly showed that it has the fight in it to get things under control. And that’s important, because the company has numerous initiatives that it believes will help it achieve growth.

Dubbed the “Magnificent Seven,” these products have either been approved or are going to be approved shortly. Management projects they will generate US$1 billion in annual revenue in five years. The products are

  • Vyzulta for glaucoma
  • Lumify for treating eye redness
  • Bausch + Lomb Ulta, which are contacts for people with astigmatism
  • Siliq for moderate to severe plaque psoriasis
  • Jemdel for psoriasis
  • Duobrii for plaque psoriasis
  • Relistor for constipation in opioid patients

But here’s one negative thing to think about: sometimes, companies will present a single drug or product that can reach US$1 billion in revenue by itself; Valeant needs seven drugs to hit that same number. So, while this is a step in the right direction, it shows that it’s going to take time to develop major blockbusters.

Valeant investors (and Papa) want to see this company reach share prices that it used to have. But if you’re going to own Valeant, you have to understand the risks. That debt still exists, and the company can only sell so many assets to get debt free without losing all of its assets. And product development takes time. Valeant could become an amazing investment, but you need to have fight in you to handle this company.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Jacob Donnelly has no position in any of the stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

money cash dividends
Stocks for Beginners

Have $500? 3 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now

If you're looking for cheap stocks, these three have a huge future ahead of them, all while costing far less…

Read more »

edit Woman in skates works on laptop
Dividend Stocks

3 No-Brainer Stocks to Buy Under $30

These three stocks all offer a huge deal for investors looking for dividends, as well as growth that will last.

Read more »

Business man on stock market financial trade indicator background.
Tech Stocks

1 Growth Stock Down 50 Percent to Buy Right Now

There are plenty of growth stocks in the market worth considering, but Shopify (TSX:SHOP) looks like one of the best…

Read more »

You Should Know This
Dividend Stocks

How to Convert a $300 Monthly Investment Into $338 in Monthly Income

If you want a certain amount in monthly passive income, invest a similar amount today and leave the rest to…

Read more »

Increasing yield
Dividend Stocks

3 Income Stocks With Big Yields to Consider in April 2024

If you haven’t yet made your March investments, here are three income stocks to buy the dip and lock in…

Read more »

Senior Man Sitting On Sofa At Home With Pet Labrador Dog
Dividend Stocks

RRSP Investors: Don’t Miss Out on This Contribution Hack!

This hack has so many benefits for you -- not just when you put it in your RRSP but for…

Read more »

edit Sale sign, value, discount
Stocks for Beginners

These 3 Growth Stocks Are on Sale and Set to Surge

Some growth stocks are on sale right now that offer massive long-term potential for investors. Here's a trio to consider…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »